Abstract
The COVID-19 pandemic, resulting in approximately seven million deaths globally, underscores the urgent need for effective treatment. Ivermectin, among several repurposed drugs, has garnered interest owing to its antiviral properties. However, conflicting evidence from observational studies and randomised controlled trials raises questions regarding its efficacy and safety.This systematic review and meta-analysis followed MOOSE and PRISMA guidelines. Comprehensive searches were conducted in databases, including Scopus, Embase, PubMed, and Web of Science up to April 2024. Data were extracted independently by two reviewers and analysed using the Comprehensive Meta-Analysis V3 software. Across 33 studies encompassing 15,376 participants, ivermectin showed no significant impact on critical outcomes such as mortality [risk ratio (RR) 0.911, 95% confidence intervals (CI) 0.732–1.135], mechanical ventilation (RR 0.727, 95% CI 0.521–1.016), polymerase chain reaction conversion (RR 1.0 24, 95% CI 0.936–1.120), ICU admissions (RR 0.712, 95% CI, 0.274–1.850), and hospitalisation rates (RR 0.735, 95% CI 0.464–1.165) compared with controls. However, it significantly reduced the time to symptom alleviation (standardised mean difference, −0.302; 95% CI, −0.587 to −0.018) and sustained symptom relief (RR 0.897, 95% CI, 0.873–0.921). The adverse event (AE) rates were similar between the ivermectin and control groups (RR 0.896, 95% CI, 0.797–1.007). Meta-regression indicated older age and diabetes as predictors of AEs. Despite its benefits in symptom management, ivermectin did not significantly influence critical clinical outcomes in COVID-19 patients. These findings highlight the importance of continued research to identify effective treatments for COVID-19, emphasising the need for high-quality studies with robust methodology to effectively inform clinical practice and public health policy.